Italia markets open in 20 minutes

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
9,17-0,53 (-5,46%)
Alla chiusura: 09:30AM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente9,70
Aperto9,17
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno9,17 - 9,17
Intervallo di 52 settimane8,12 - 15,80
Volume270
Media Volume1.755
Capitalizzazione5,905B
Beta (5 anni mensile)0,67
Rapporto PE (ttm)101,89
EPS (ttm)0,09
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendo03 giu 2021
Stima target 1AN/D
  • GlobeNewswire

    GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564

    Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade GigaGen and NCI will present investigational new drug (IND)-enabling data and clinical trial strategy for GIGA-564 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting SAN CARLOS, Calif., Sept. 28, 2023 (GLOBE NEWSW

  • GlobeNewswire

    Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

    Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and

  • GlobeNewswire

    Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

    Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business st